228559-41-9 KI8751 AKSci J53091
 
 
Loading Please Wait...
  J53091    
KI8751
, 95%
 
N-(2,4-difluorophenyl)-N''-(4-((6,7-dimethoxy-4-quinolyl)oxy)-2-fluorophenyl)urea




IDENTITY
CAS Number:228559-41-9
MDL Number:MFCD09971092
MF:C24H18F3N3O4
MW:469.41
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:95%
Physical Form (at 20°C):Solid
Melting Point:235-238°C
Long-Term Storage:Store long-term at -20°C
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:DMSO =92mg/mL Water <1.2mg/mL Ethanol <1.2mg/ml
Application(s):Inhibitor of VEGFR2, PDGFR-alpha and c-Kit
Form:Free Base
Research Area:Cancer

REVIEW

 Ki8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM, >40-fold selective for VEGFR2 than c-Kit, PDGFR-alfa and FGFR-2, little activity to EGFR, HGFR and InsR. IC50 value: 0.9 nM. Target: VEGFR2 in vitro: Ki8751 potently and selectively inhibits VEGFR2 with IC50 of 0.9 nM. Ki8751 also inhibits PDGFR-alfa, c-Kit, and FGFR-2, with much higher IC50 values (40 nM-170 nM). Except for these several kinases, Ki8751 doesn''t disturb other kinases, including HGFR, EGFR, and InsulinR, even at 10 µM. In human umbilical vein endothelial cells (HUVECs), Ki8751 (1 nM-100 nM) effectively decreases VEGF-stimulated cell proliferation and vasculature permeability. In metastatic colorectal cancer (CRC) cells MIP, RKO, SW620, and SW480, but not in HCT116, Ki8751 (10 nM) increases cellular senescence. in vivo: In nude mice bearing human tumor xenografts of GL07, St-4, LC6, DLD-1, and A375 cells, Ki8751 (20 mg/kg) inhibits tumor growth. In nude rat xenograft models of LC-6 cells, Ki8751 (5 mg/kg) completely inhibits tumor growth without affecting body weight.

REFERENCES
[1]Hasan MR, et al. Inhibition of VEGF induces cellular senescence in colorectal cancer cells. Int J Cancer, 2011, 129(9), 2115-2123.
[2] Tamura D, et al. Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition. Cancer Sci, 2010, 101(6), 1403-1408.
[3] 'Kubo K, et al. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N''-{4-(4-quinolyloxy)phenyl}ureas. J Med Chem, 2005, 48(5), 1359-1366.'
[4] Kubo, Kazuo; Journal of Medicinal Chemistry 2005, V48(5), P1359-1366

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of April 19, 2024


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.



CATEGORIES

 APIs and Bioactives >


PubChem